Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer

BioImpacts

Volumn 4, Issue 1, 2014, Pages 3-14

  Barar, Jaleh ^a,b   Omidi, Yadollah ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer diagnosis; Cancer imaging; Cancer therapy; Nanomedicine; Theranostics

Indexed keywords

CARBON NANOTUBE; CROSS LINKING REAGENT; DOXORUBICIN; GOLD NANOPARTICLE; LIPID; MAGNETIC NANOPARTICLE; NANOPARTICLE; NANOSHELL; POLYMER; QUANTUM DOT; SILICA NANOPARTICLE; UNCLASSIFIED DRUG;

ALLERGIC REACTION; CANCER CHEMOTHERAPY; CELL HOMING; CHEMICAL BOND; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; COMPLEMENT ACTIVATION; CONJUGATION; DNA STRAND; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SAFETY; HUMAN; HYDROPHILICITY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR IMAGING; NANOMEDICINE; NANOPHARMACEUTICS; NONHUMAN; OPSONIZATION; REVIEW; SURFACE PROPERTY; SYSTEMATIC REVIEW;

EID: 84898640100     PISSN: 22285652     EISSN: 22285660     Source Type: Journal    
DOI: 10.5681/bi.2014.011     Document Type: Review

References (110)

1. Barar J, Omidi Y. Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy. Bioimpacts 2013; 3: 149-62.
2. Cappellani A, Zanghi A, Di Vita M, Zanet E, Veroux P, Cacopardo B, et al. Clinical and biological markers in gastric cancer: update and perspectives. Front Biosci (Schol Ed) 2010; 2: 403-12.
3. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 2009; 18: 81-100.
4. Kandalaft LE, Powell DJ, Jr., Singh N, Coukos G. Immunotherapy for ovarian cancer: what's next? J Clin Oncol 2010; 29: 925-33.
5. Vafadar-Isfahani B, Laversin SA, Ahmad M, Ball G, Coveney C, Lemetre C, et al. Serum biomarkers which correlate with failure to respond to immunotherapy and tumor progression in a murine colorectal cancer model. Proteomics Clin Appl 2010; 4: 682-96.
6. Omidi Y. Smart Multifunctional Theranostics: Simultaneous Diagnosis and Therapy of Cancer. BioiImpacts 2011; 1: 145-7.
7. Grimm J, Scheinberg DA. Will nanotechnology influence targeted cancer therapy? Semin Radiat Oncol 2011; 21: 80-7.
8. Omidi Y, Dolatabadi JEN, Mashinchian O, Ayoubi B, Jamali AA, Mobed A, et al. Optical and electrochemical DNA nanobiosensors. Trac-Trends in Analytical Chemistry 2011; 30: 459-72.
9. Dolatabadi JEN, Omidi Y, Losic D. Carbon Nanotubes as an Advanced Drug and Gene Delivery Nanosystem. Curr Nanosci 2011; 7: 297-314.
10. Plassat V, Martina MS, Barratt G, Menager C, Lesieur S. Sterically stabilized superparamagnetic liposomes for MR imaging and cancer therapy: pharmacokinetics and biodistribution. Int J Pharm 2007; 344: 118-27.
11. Ramachandran S, Quist AP, Kumar S, Lal R. Cisplatin nanoliposomes for cancer therapy: AFM and fluorescence imaging of cisplatin encapsulation, stability, cellular uptake, and toxicity. Langmuir 2006; 22: 8156-62.
12. Sofou S, Enmon R, Palm S, Kappel B, Zanzonico P, McDevitt MR, et al. Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. J Liposome Res 2010; 20: 330-40.
13. Nurunnabi M, Cho KJ, Choi JS, Huh KM, Lee YK. Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. Biomaterials 2010; 31: 5436-44.
14. Kang KW, Chun MK, Kim O, Subedi RK, Ahn SG, Yoon JH, et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine 2010; 6: 210-3.
15. Khan MK, Nigavekar SS, Minc LD, Kariapper MS, Nair BM, Lesniak WG, et al. In vivo biodistribution of dendrimers and dendrimer nanocomposites-implications for cancer imaging and therapy. Technol Cancer Res Treat 2005; 4: 603-13.
16. Rosenholm JM, Sahlgren C, Linden M. Multifunctional mesoporous silica nanoparticles for combined therapeutic, diagnostic and targeted action in cancer treatment. Curr Drug Targets 2011; 12: 1166-86.
17. Mamaeva V, Rosenholm JM, Bate-Eya LT, Bergman L, Peuhu E, Duchanoy A, et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol Ther 2011; 19: 1538-46.
18. Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010; 4: 4539-50.
19. Cho YS, Yoon TJ, Jang ES, Soo Hong K, Young Lee S, Ran Kim O, et al. Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. Cancer Lett 2010; 299: 63-71.
20. Carpin LB, Bickford LR, Agollah G, Yu TK, Schiff R, Li Y, et al. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res Treat 2011; 125: 27-34.
21. Krishna V, Singh A, Sharma P, Iwakuma N, Wang Q, Zhang Q, et al. Polyhydroxy fullerenes for non-invasive cancer imaging and therapy. Small 2010; 6: 2236-41.
22. Lay CL, Liu HQ, Tan HR, Liu Y. Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graft-carbon nanotubes for potent cancer therapeutics. Nanotechnology 2010; 21: 065101.
23. Kang B, Yu D, Dai Y, Chang S, Chen D, Ding Y. Cancer-cell targeting and photoacoustic therapy using carbon nanotubes as "bomb" agents. Small 2009; 5: 1292-301.
24. Kishwar S, Asif MH, Nur O, Willander M, Larsson PO. Intracellular ZnO Nanorods Conjugated with Protoporphyrin for Local Mediated Photochemistry and Efficient Treatment of Single Cancer Cell. Nanoscale Res Lett 2010; 5: 1669-74.
25. Yang HM, Park CW, Woo MA, Kim MI, Jo YM, Park HG, et al. HER2/neu Antibody Conjugated Poly(amino acid)-Coated Iron Oxide Nanoparticles for Breast Cancer MR Imaging. Biomacromolecules 2010; 11: 2866-72.
26. Lee J, Choi Y, Kim K, Hong S, Park HY, Lee T, et al. Characterization and cancer cell specific binding properties of anti-EGFR antibody conjugated quantum dots. Bioconjug Chem 2010; 21: 940-6.
27. Ferreira CS, Papamichael K, Guilbault G, Schwarzacher T, Gariepy J, Missailidis S. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours. Anal Bioanal Chem 2008; 390: 1039-50.
28. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-90.
29. Wang K, Ruan J, Qian Q, Song H, Bao C, Zhang X, et al. BRCAA1 monoclonal antibody conjugated fluorescent magnetic nanoparticles for in vivo targeted magnetofluorescent imaging of gastric cancer. J Nanobiotechnology 2011; 9: 23.
30. El-Sayed IH, Huang X, El-Sayed MA. Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. Nano Lett 2005; 5: 829-34.
31. Bhirde AA, Patel V, Gavard J, Zhang G, Sousa AA, Masedunskas A, et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 2009; 3: 307-16.
32. Omidi Y. CNT Nanobombs for Specific Eradication of Cancer Cells: A New Concept in Cancer Theranostics. Bioimpacts 2011; 1: 199-201.
33. Tan A, Yildirimer L, Rajadas J, De La Pena H, Pastorin G, Seifalian A. Quantum dots and carbon nanotubes in oncology: a review on emerging theranostic applications in nanomedicine. Nanomedicine (Lond) 2011; 6: 1101-14.
34. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005; 307: 538-44.
35. Sukhanova A, Nabiev I. Fluorescent nanocrystal quantum dots as medical diagnostic tools Expert Opin Med Diagn 2008; 2: 429-47.
36. Murray CB, Norris DJ, Bawendi MG. Synthesis and Characterization of Nearly Monodisperse CdE (E = S, Se, Te) Semiconductor Nanocrystallites. J Am Chem Soc 1993; 115: 8706-15
37. Dabbousi BO, Rodriguez-Viejo J, Mikulec FV, Heine JR, Mattouss IH, Ober R, et al. (CdSe)ZnS core-shell quantum dots: Synthesis and characterization of a size series of highly luminescent nanocrystallites. J Phys Chem 1997; B101: 9463-75.
38. Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003; 21: 41-6.
39. Jamieson T, Bakhshi R, Petrova D, Pocock R, Imani M, Seifalian AM. Biological applications of quantum dots. Biomaterials 2007; 28: 4717-32.
40. Biju V, Itoh T, Anas A, Sujith A, Ishikawa M. Semiconductor quantum dots and metal nanoparticles: syntheses, optical properties, and biological applications. Anal Bioanal Chem 2008; 391: 2469-95.
41. Obonyo O, Fisher E, Edwards M, Douroumis D. Quantum dots synthesis and biological applications as imaging and drug delivery systems. Crit Rev Biotechnol 2010; 30: 283-301.
42. Rosenthal SJ, Chang JC, Kovtun O, McBride JR, Tomlinson ID. Biocompatible quantum dots for biological applications. Chem Biol 2011; 18: 10-24.
43. Dolatabadi JEN, Mashinchian O, Ayoubi B, Jamali AA, Mobed A, Losic D, et al. Optical and electrochemical DNA nanobiosensors. TrAC Trends in Analytical Chemistry 2011; 30: 459-72.
44. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtar S. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin-and oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target 2003; 11: 311-23.
45. Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr Drug Deliv 2005; 2: 429-41.
46. Omidi Y, Hollins AJ, Drayton RM, Akhtar S. Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type. J Drug Target 2005; 13: 431-43.
47. Hollins AJ, Omidi Y, Benter IF, Akhtar S. Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J Drug Target 2007; 15: 83-8.
48. Omidi Y, Barar J, Heidari HR, Ahmadian S, Yazdi HA, Akhtar S. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial a549 cells. Toxicol Mech Methods 2008; 18: 369-78.
49. Barar J, Hamzeiy H, Mortazavi Tabatabaei SA, Hashemi-Aghdam SE, Omidi Y. Genomic signature and toxicogenomics comparison of polycationic gene delivery nanosystems in human alveolar epithelial A549 cells. Daru 2009; 17: 139-47.
50. Omidi Y, Barar J. Induction of human alveolar epithelial cell growth factor receptors by dendrimeric nanostructures. Int J Toxicol 2009; 28: 113-22.
51. Barar J, Omidi Y. Cellular Trafficking and Subcellular Interactions of Cationic Gene Delivery Nanomaterials. J Pharm Nut Sci 2011; 1: 68-81.
52. Kafil V, Omidi Y. Cytotoxic Impacts of Linear and Branched Polyethylenimine Nanostructures in A431 Cells. BioiImpacts 2011; 1: 23-30.
53. Barar J, Omidi Y. Intrinsic bio-signature of gene delivery nanocarriers may impair gene therapy goals. Bioimpacts 2013; 3: 105-9.
54. Yan M, Zhang Y, Xu K, Fu T, Qin H, Zheng X. An in vitro study of vascular endothelial toxicity of CdTe quantum dots. Toxicology 2011; 282: 94-103.
55. Hoshino A, Hanada S, Yamamoto K. Toxicity of nanocrystal quantum dots: the relevance of surface modifications. Arch Toxicol 2011; 85: 707-20.
56. Kennedy LC, Bickford LR, Lewinski NA, Coughlin AJ, Hu Y, Day ES, et al. A new era for cancer treatment: gold-nanoparticle-mediated thermal therapies. Small 2011; 7: 169-83.
57. Benezra M, Penate-Medina O, Zanzonico PB, Schaer D, Ow H, Burns A, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest 2011; 121: 2768-80.
58. Huang IP, Sun SP, Cheng SH, Lee CH, Wu CY, Yang CS, et al. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Mol Cancer Ther 2011; 10: 761-9.
59. Santra S. Fluorescent silica nanoparticles for cancer imaging. Methods Mol Biol 2010; 624: 151-62.
60. Thakare VS, Das M, Jain AK, Patil S, Jain S. Carbon nanotubes in cancer theragnosis. Nanomedicine (Lond) 2010; 5: 1277-301.
61. Ilbasmis-Tamer S, Yilmaz S, Banoglu E, Degim IT. Carbon nanotubes to deliver drug molecules. J Biomed Nanotechnol 2010; 6: 20-7.
62. Tao H, Yang K, Ma Z, Wan J, Zhang Y, Kang Z, et al. In Vivo NIR Fluorescence Imaging, Biodistribution, and Toxicology of Photoluminescent Carbon Dots Produced from Carbon Nanotubes and Graphite. Small 2011.
63. Vilela D, Anson-Casaos A, Martinez MT, Gonzalez MC, Escarpa A. High NIR-purity index single-walled carbon nanotubes for electrochemical sensing in microfluidic chips. Lab Chip 2012; 12: 2006-14.
64. Levi-Polyachenko NH, Merkel EJ, Jones BT, Carroll DL, Stewart JHT. Rapid photothermal intracellular drug delivery using multiwalled carbon nanotubes. Mol Pharm 2009; 6: 1092-9.
65. Zhou F, Xing D, Ou Z, Wu B, Resasco DE, Chen WR. Cancer photothermal therapy in the near-infrared region by using single-walled carbon nanotubes. J Biomed Opt 2009; 14: 021009.
66. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008; 68: 6652-60.
67. Bhirde AA, Patel S, Sousa AA, Patel V, Molinolo AA, Ji Y, et al. Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. Nanomedicine (Lond) 2010; 5: 1535-46.
68. Gannon CJ, Cherukuri P, Yakobson BI, Cognet L, Kanzius JS, Kittrell C, et al. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer 2007; 110: 2654-65.
69. Sajja HK, East MP, Mao H, Wang YA, Nie S, Yang L. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol 2009; 6: 43-51.
70. Petri-Fink A, Hofmann H. Superparamagnetic iron oxide nanoparticles (SPIONs): from synthesis to in vivo studies-a summary of the synthesis, characterization, in vitro, and in vivo investigations of SPIONs with particular focus on surface and colloidal properties. IEEE Trans Nanobioscience 2007; 6: 289-97.
71. Johannsen M, Thiesen B, Wust P, Jordan A. Magnetic nanoparticle hyperthermia for prostate cancer. Int J Hyperthermia 2010; 26: 790-5.
72. Johannsen M, Gneveckow U, Taymoorian K, Thiesen B, Waldofner N, Scholz R, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia 2007; 23: 315-23.
73. Curvo-Semedo L, Diniz M, Migueis J, Juliao MJ, Martins P, Pinto A, et al. USPIO-enhanced magnetic resonance imaging for nodal staging in patients with head and neck cancer. J Magn Reson Imaging 2006; 24: 123-31.
74. Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, et al. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging 2009; 33: 301-5.
75. Heesakkers RA, Hovels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008; 9: 850-6.
76. Shubayev VI, Pisanic TR, 2nd, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 2009; 61: 467-77.
77. Heidari Majd M, Asgari D, Barar J, Valizadeh H, Kafil V, Coukos G, et al. Specific targeting of cancer cells by multifunctional mitoxantrone-conjugated magnetic nanoparticles. J Drug Target 2013; 21: 328-40.
78. Heidari Majd M, Asgari D, Barar J, Valizadeh H, Kafil V, Abadpour A, et al. Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer. Colloids Surf B Biointerfaces 2013; 106: 117-25.
79. Yallapu MM, Foy SP, Jain TK, Labhasetwar V. PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharm Res 2010; 27: 2283-95.
80. Nakhlband A, Barar J, Bidmeshkipour A, Heidari HR, Omidi Y. Bioimpacts of anti epidermal growth factor receptor antisense complexed with polyamidoamine dendrimers in human lung epithelial adenocarcinoma cells. J Biomed Nanotechnol 2010; 6: 360-9.
81. Vicent MJ, Ringsdorf H, Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev 2009; 61: 1117-20.
82. Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 2006; 45: 1198-215.
83. Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol 2011; 22: 492-501.
84. Hermanson GT. Bioconjugate Techniques. 2nd ed. Amesterdam: Elsevier Inc.; 2008.
85. Shin IS, Jang BS, Danthi SN, Xie J, Yu S, Le N, et al. Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature. Bioconjug Chem 2007; 18: 821-8.
86. Schellenberger EA, Sosnovik D, Weissleder R, Josephson L. Magneto/optical annexin V, a multimodal protein. Bioconjug Chem 2004; 15: 1062-7.
87. Schellenberger EA, Reynolds F, Weissleder R, Josephson L. Surface-functionalized nanoparticle library yields probes for apoptotic cells. Chembiochem 2004; 5: 275-9.
88. Strehblow C, Schuster M, Moritz T, Kirch HC, Opalka B, Petri JB. Monoclonal antibody-polyethyleneimine conjugates targeting Her-2/neu or CD90 allow cell type-specific nonviral gene delivery. J Control Release 2005; 102: 737-47.
89. Yang LJ, Sui YF, Chen ZN. Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab')(2) fragment and staphylococcal enterotoxin A. World J Gastroenterol 2001; 7: 216-21.
90. Hoppmann S, Miao Z, Liu S, Liu H, Ren G, Bao A, et al. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjug Chem 2011; 22: 413-21.
91. Pereira M, Lai EP. Capillary electrophoresis for the characterization of quantum dots after non-selective or selective bioconjugation with antibodies for immunoassay. J Nanobiotechnology 2008; 6: 10.
92. Frasco MF, Chaniotakis N. Bioconjugated quantum dots as fluorescent probes for bioanalytical applications. Anal Bioanal Chem 2009; 396: 229-40.
93. Chan WC, Maxwell DJ, Gao X, Bailey RE, Han M, Nie S. Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol 2002; 13: 40-6.
94. Chang YP, Pinaud F, Antelman J, Weiss S. Tracking bio-molecules in live cells using quantum dots. J Biophotonics 2008; 1: 287-98.
95. Xing Y, Chaudry Q, Shen C, Kong KY, Zhau HE, Chung LW, et al. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc 2007; 2: 1152-65.
96. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005; 4: 435-46.
97. Wang Y, Chen L. Quantum dots, lighting up the research and development of nanomedicine. Nanomedicine 2011; 7:385-402.
98. Wagner MK, Li F, Li J, Li XF, Le XC. Use of quantum dots in the development of assays for cancer biomarkers. Anal Bioanal Chem 2010; 397: 3213-24.
99. Chan LW, Wang YN, Lin LY, Upton MP, Hwang JH, Pun SH. Synthesis and characterization of anti-EGFR fluorescent nanoparticles for optical molecular imaging. Bioconjug Chem 2013; 24: 167-75.
100. Girgis MD, Federman N, Rochefort MM, McCabe KE, Wu AM, Nagy JO, et al. An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles. J Surg Res 2013; 185: 45-55.
101. Wang Y, Liu P, Duan Y, Yin X, Wang Q, Liu X, et al. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer. Biomaterials 2014; 35: 983-92.
102. Feng G, Li K, Liu J, Ding D, Liu B. Bright single-chain conjugated polymer dots embedded nanoparticles for long-term cell tracing and imaging. Small 2014; 10: 1212-9.
103. Shan X, Yuan Y, Liu C, Tao X, Sheng Y, Xu F. Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles. Biomed Microdevices 2009; 11: 1187-94.
104. Owens DE, 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307: 93-102.
105. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003; 42: 463-78.
106. Szebeni J, Bedocs P, Rozsnyay Z, Weiszhar Z, Urbanics R, Rosivall L, et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 2011; 8:176-84.
107. Moghimi SM, Andersen AJ, Hashemi SH, Lettiero B, Ahmadvand D, Hunter AC, et al. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J Control Release 2010; 146: 175-81.
108. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003; 14: 1430-7.
109. Cui L, Cohen JA, Broaders KE, Beaudette TT, Frechet JM. Mannosylated dextran nanoparticles: a pH-sensitive system engineered for immunomodulation through mannose targeting. Bioconjug Chem 2011; 22: 949-57.
110. Hamelers IH, Staffhorst RW, Voortman J, de Kruijff B, Reedijk J, van Bergen en Henegouwen PM, et al. High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis. Clin Cancer Res 2009; 15: 1259-68.